Back to search

National and Kapodistrian University of Athens

Μελέτη της in vitro δραστικότητας της κεφντιτορένης έναντι στελεχών Streptococcus pneumoniae και εντεροβακτηριακών απομονωθέντων από εξωνοσοκομειακές λοιμώξεις

Abstract

dc:description

Background: Increasing antibiotic resistance among Streptococcus pneumoniae as wellas uropathogens imposes difficulties in the empirical treatment of community acquiredpneumococcal infections, as well as community Urinary Tract Infections (cUTI).Cefditoren pivoxil is a 3rd generation oral cephalosporin that was recently licensed inGreece for the treatment of community acquired pneumococcal infections and has beenlicensed for cUTIs only in Japan.Purpose: The purpose of the present study was to evaluate the in vitro efficacy andkilling kinetic profile of cefditoren against recently isolated S. pneumoniae isolates fromcommunity acquired infections, as well as recently isolated uropathogens fromcommunity acquired Urinary Tract Infections in Greece.Methods: A total of 338 S. pneumoniae strains, isolated during 2004-2006 from clinicalspecimens of adults and children as well as from nasopharyngeal swabs of preschoolhealthy children were tested against 10 antibiotics by E-test method, according to CLSIrecommendations, except from cefditoren, which was tested by agar dilution method. Inlack of CLSI / EUCAST established breakpoints, isolates with MIC ≥2 mg/L wereconsidered as resistant, according to the recent literature.The susceptibility of 563 Gram (-) isolates recovered during 2005-2007 frompatients with complicated and uncomplicated UTIs treated as outpatients, were testedagainst 19 antibiotics, including the most commonly used in the community, by diskdiffusion method and by E-test method for ciprofloxacin (CLSI 2011). Thesusceptibility of the microorganisms to cefditoren was tested by agar dilution method.Isolates with MIC ≥2 mg/L were considered as resistant, according to the recentliterature.The killing kinetic profile of cefditoren was also evaluated by killing curves for 20S. pneumoniae isolates and for 20 Enterobacteriaceae isolates (16 Escherichia coli and4 Klebsiella pneumoniae), using concentrations of 1x, 2x and 4x MIC and within 0, 2,4, 6, 8, 10, 12 and 24 hours of incubation for S. pneumoniae strains and for 0, 2, 4, 6and 24 hours of incubation for Enterobactericeae strains. Results: A total of 337 isolates of S. pneumoniae was studied, 91.1% of which weresusceptible to penicillin, 8,6% were intermediate and 0.3% were resistant, with respectto CLSI 2011 non-meningitic breakpoints for parenteral use of penicillin. For cefditorenin total, resistance rates were 1.2% (4/337). Cefditoren was efficacious against S.pneumoniae isolates irrespective of the presence of penicillin non-susceptibility. Nonsusceptibilityrates (intermediate resistance plus resistance rates) for the rest of theagents tested were: cefuroxime 40.8%, ceftriaxone 2.7%, erythromycin 59.3%,tetracycline 43.9%, cotrimoxazole 62.8% and ciprofloxacin 4.9%. All strains weresusceptible to levofloxacin and moxifloxacin. Only cotrimoxazole displayedsignificantly different non-susceptibility rates between clinical and carriagepneumococcal isolates (45.1 vs 65.9% respectively, P= 0.007). MIC values wereavailable for the whole antimicrobial agent panel for 321/337 pneumococcal isolates(95.3%). Strains susceptible to all agents tested accounted for 20.6% (66/321).Multiresistance was not associated with the source of the culture. Cefditoren nonsusceptibilitywas evident in strains concurrently resistant to 5 agents.A total of 563 Enterobacteriaceae isolates (330 Escherichia coli, 142 Proteusmirabilis and 91 Klebsiella spp) was studied. MIC50 / MIC90 of cefditoren was 0.25 / 0.5mg/L respectively, with 97.1% of the isolates being inhibited at 1 mg/L. All 9 strainsproducing ESBL enzymes were resistant to cefditoren. Susceptibility rates % foramoxycillin / clavulanic acid, cefuroxime axetil, cefotaxime, ciprofloxacin,trimethoprim / sulfamethoxazole and fosfomycin were 93.1, 94.1, 96.8, 93.1, 71.9 and92.8 respectively. Cefditoren MIC was significantly higher in nalidixic / ciprofloxacinnon-susceptible strains. Resistance to cefditoren was not associated with resistance tomecillinam, fosfomycin, nitrofurantoin and aminoglycosides. Multivariate analysisdemonstrated history of urinary tract infection in the last two weeks or three months asrisk factors for cefditoren resistance.The killing kinetic studies, by killing curves, showed that cefditoren displayed cidalactivity within 24 hours against all S. pneumoniae and Enterobacteriaceae strainsstudied (susceptible and non-susceptible to cefditoren), by decreasing the initialinoculums at least 3log10. For cefditoren susceptible strains (0.125 - 1 mg/L) killingeffect was evident within 6 hours at concentrations equal to 4x MIC. Conclusions: Cefditoren exerted an excellent in vitro antibacterial activity, retaininglow MICs against S. pneumoniae strains displaying resistance to penicillin anderythromycin, although statistically significant differences in MIC distribution wereobserved between penicillin non-susceptible and susceptible strains and erythromycinnon-susceptible and susceptible strains. Cefditoren could prove a valuable alternative toexisting drugs for community acquired pneumococcal infections treated in theoutpatient setting.Cefditoren also exhibited enhanced in vitro activity against the most commonuropathogens in the outpatient setting, representing an alternative oral treatment optionfor UTIs in patients with risk factors for resistance to first-line antibiotics. Clinicalstudies are warranted to clearly define its possible role in the treatment of UTIs inoutpatients.Cefditoren also, displaying a rapid killing effect both for S. pneumoniae and forEnterobacteriaceae, could prove a useful adjunction to the antibiotic outpatientarmamentarium, but implementation of breakpoints and continuous surveillance ofresistance are needed.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Hatzaki, Despina
  • Χατζάκη, Δέσποινα

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/41462

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Hatzaki, Despina; Χατζάκη, Δέσποινα. Μελέτη της in vitro δραστικότητας της κεφντιτορένης έναντι στελεχών Streptococcus pneumoniae και εντεροβακτηριακών απομονωθέντων από εξωνοσοκομειακές λοιμώξεις. National and Kapodistrian University of Athens, 2013. http://hdl.handle.net/10442/hedi/41462